Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Clearside BioMedical Inc (Clearside) is a clinical biopharmaceutical company that develops treatments for vision impairment associated with uveitic macular edema. The company’s pipeline products include CLS-AX for the treatment of wet age-related macular degeneration (AMD); Bel-Sar targets choroidal melanoma; ABBV-RGX-314 for diabetic retinopathy; Avoralstat is for the treatment of diabetic macular edema; XIPERE treats uveitic macular edema. Clearside has partnered with various pharmaceutical companies for the commercialization and development of its products across the US, Canada, China, Hong Kong, Macau, Taiwan and South Korea, among others. It markets its products across the US. Clearside is headquartered in Alpharetta, Georgia, the US.
Headquarters
United States of America
Address
900 North Point Parkway, Suite 200, Alpharetta, Georgia, 30005
Website
clearsidebio.com
Telephone
1 678 2703631
No of Employees
32
Industry
Medical Equipment
Ticker Symbol & Exchange
CLSDQ (OTC)
Revenue (2023)
$1.7M
-79.8%
(2023 vs 2022)
EPS
XYZ
Net Income (2023)
XYZ
-5.7%
(2023 vs 2022)
Market Cap*
$1.3M
Net Profit Margin (2023)
XYZ
-422.8%
(2023 vs 2022)
* As of and is in US$
Products and Services
| Products | Brands |
|---|---|
| Pipeline | XIPERE |
| CLS-AX: Wet Age-related Macular Degeneration (AMD) | SCS Microinjector |
| Bel-Sar: Choroidal Melanoma | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Bankruptcy Filing | In November, the company filed for Chapter 11 bankruptcy. |
| 2023 | Contracts/Agreements | In November, the company entered into a partnership with BioCryst to develop its investigational plasma kallikrein inhibitor, avoralstat, with Clearside’s SCS Microinjector. |
| 2022 | Contracts/Agreements | In August, the company entered into an agreement to acquire Royalty Interest from HealthCare Royalty Partners. |
Competitor Comparison
| Key Parameters | Clearside BioMedical Inc | Boston Scientific Corp | Vyome Holdings Inc | Advanced Vision Science Inc | Apollo Endosurgery Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Alpharetta | Marlborough | San Clemente | Goleta | - |
| State/Province | Georgia | Massachusetts | California | California | Delaware |
| No. of Employees | 32 | 59,000 | 9 | 40 | 139 |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Anthony S. Gibney | Chairman | Executive Board | 2024 | 54 |
| George Lasezkay, PhD | Chief Executive Officer; Director; President | Executive Board | 2020 | 73 |
| Charles A. Deignan | Chief Financial Officer | Senior Management | 2012 | 60 |
| Victor Chong, MD | Chief Medical Officer; Head - Research and Development; Executive Vice President | Senior Management | 2024 | 59 |
| Rick McElheny | Senior Vice President - Corporate Development and Alliance Management | Senior Management | 2016 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer